BTG Share PerformanceMore
|52 week high||739.5 12/07/16|
|52 week low||528.4 31/01/17|
|52 week change||-37.5 (-6.03%)|
|4 week volume||13,354,363 03/03/17|
Latest News« previous» nextMore
02/03/2017 - 15:03 RNS
RNS Number: 3813Y BTG PLC 02 March 2017 2 March 2017 BTG plc - To tal Voting Rights and Share Capital In accordance with FCA's Disclosure and Transparency Rule 5.6.1, BTG plc (the "Company") notifies that as at 2 March 2017: 1. the Company's issued share capital consists of 385,127,525 Ordinaryshares of 10p each admitted to trading, and each with one vote; 2....
27/02/2017 - 14:10 StockMarketWire
BTG has received 510(k) clearance from the US Food and Drug Administration in respect of its EKOS Control Unit 4.0, use...
27/02/2017 - 14:02 RNS
RNS Number: 9151X BTG PLC 27 February 2017 BTG Receives U.S. FDA 510(k) Clearance for EKOS Control Unit 4.0 London, UK, 27 February 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announced U.S. Food and Drug Administration 510(k) clearance has been granted to the EKOS Control Unit 4.0. The EKOS system includes an ultraso...
01/02/2017 - 13:10 RNS
RNS Number: 7604V BTG PLC 01 February 2017 1 February 2017 BTG plc - To tal Voting Rights and Share Capital In accordance with FCA's Disclosure and Transparency Rule 5.6.1, BTG plc (the "Company") notifies that as at 1 February 2017: 1. the Company's issued share capital consists of 385,099,960 Ordinaryshares of 10p each admitted to trading, and each with one...
26/01/2017 - 11:30 StockMarketWire
Deutsche Bank today reaffirms its buy investment rating on BTG PLC (LON:BTG) and cut its price target to 775p (from 8...
25/01/2017 - 12:10 StockMarketWire
Peel Hunt today initiates coverage of BTG PLC (LON:BTG) with a hold investment rating and price target of 630p.
24/01/2017 - 10:10 StockMarketWire
Jefferies International today reaffirms its buy investment rating on BTG PLC (LON:BTG) and cut its price target to 775p (...
05/01/2017 - 15:10 StockMarketWire
Panmure Gordon today reaffirms its buy investment rating on BTG PLC (LON:BTG) and set its price target at 737p.
|Dividend yield||0 %|
Equity Research (BTG)
Growth across all three divisions of BTG’s Interventional Medicine (IM) franchise (oncology, vascular and pulmonology), coupled with currency tailwinds, helped push FY16 revenue towards the upper end...
BTG’s interim results have driven upgrades to our financial forecasts with a small boost to revenues from one-off Zytiga backdated royalties. Our operating expenses are broadly unchanged, but...
BTG’s close period update saw a revision to its FY16 revenue guidance, targeting sales in the lower half of £410-440m (at $1.61/£). This is based on slower-than-expected Varithena sales, despite a...
- 1 of 3
Latest discussion posts More
“Paulo, If you look back about 14 yrs (as No 1 cost centre is coming up to 17!) this is why I got into Protherics in the first place. My problem was that the company is ...”▼
“Anti-Venom Market is projected to reach USD 1493.2 million by 2021, at a CAGR of 6.12%. Press release from: Market Data Forecast According to the report Global ...”▼
“Dave, "I fear how ever, that you might be bailing out a tad early" Mea culpa, but I have sold. Watch with interest. If I had seen, even thought, BoD were managing this ...”▼
Codes & Symbols
|Symbols||BTG, LSE:BTG, BTG.L, BTG:LN, LON:BTG, XLON:BTG|